Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced it has launched Rocuronium Bromide Injection Room Temperature Stable (RTS), the first formulation of Rocuronium Bromide Injection that does not require refrigeration.
Health Technology Insights: NeuroSigma Invests $1Million in 2nd Gen Monarch eTNS Manufacturing
Fresenius Kabi announces the launch Rocuronium Bromide Injection Room Temperature Stable (RTS), the first formulation of Rocuronium Bromide Injection that does not require refrigeration.
Rocuronium Bromide Injection RTS was formulated to be stored at room temperature, eliminating the need for refrigeration, which is expected to streamline logistics.
Health Technology Insights: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer
Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Because it can be stored at room temperature, Rocuronium Bromide Injection RTS is expected to reduce the cost and complexity of transportation and storage because a cold supply chain is not needed. Hospital pharmacies can store Rocuronium Bromide Injection RTS at room temperature, which can free up refrigerated space for other medications.
Rocuronium Bromide Injection RTS is formulated, filled, and packaged in the United States at Fresenius Kabi’s facility in Grand Island, New York. Since 2017, Fresenius Kabi has invested nearly $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. More than 70% of the units shipped by Fresenius Kabi in the U.S. are drugs listed on the FDA’s Essential Medicines List.
“The introduction of Rocuronium Bromide Injection RTS highlights our leadership in providing innovative solutions that help customers improve efficiency and deliver quality care,” said Joel Rosenstack, president, U.S. Pharmaceuticals. “Our strong commitment to U.S. manufacturing helps ensure a reliable supply for patients and clinicians.”
Fresenius Kabi’s Rocuronium Bromide Injection RTS is available in two presentations: 50 mg per 5 mL and 100 mg per 10 mL.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 15 December 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
